Share Price, page-11125

I'm onboard with Gingerclam's view that the share price is low because enough are willing to take the risk that the near future will be driven by poorer financials (only in comparison to the last year of course) and that a TO won't come out of the blue and they miss the boat for a new upward surge. Any takeover offer that's presented will surely be pushing this to new highs and is not one I would want to miss or have any idea of timing so I'm not making that play. But it is reasonable to say that the Daybue story was front-ended with the upside and so recent results have been seen as a miss and trended things down. Acadia only needs to hit 2 quarters of $90 million to make bottom end of guidance and I expect they can do better than that so not expecting much room to go lower now. Impending upside too could come soon from announcements about new indications with strong mouse data and a PR push saying all these previous animal studies have translated to humans. Also a positive take on the P3 discussions with the FDA or PRV sale. So in my simple summary - way undervalued on broad fundamentals, negative news already out and correction made. Near term really only things to get excited about and supported by analysts valuations. So a buy IMO.